EN DE
Watch Brii Biosciences Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Brii Biosciences Ltd (2137) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Brii Biosciences Ltd stock HK$0.88, price HK$1.05, that is 16.2% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG1645A1094

BB Brii Biosciences Ltd logo Thin data Nov 10, 2026

Brii Biosciences Ltd

2137 · HK
Expensive, in a downtrend

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Ranks above peers (7/8)
Revenue last quarter +24% vs. a year ago.
Quality 50/100
Fair value HK$0.8800 · Overvalued
Weak Growth (revenue 5y −26.1 %/yr in CNY)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Brii Biosciences Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$50.90 HK$0.8200 Fair Value HK$0.8800 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.8200 – HK$50.90 · fair‑value band HK$0.6600 – HK$1.10 · the HK$1.05 price screens above the HK$0.8800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Brii Biosciences in your weekly email

Every Wednesday you see whether Brii Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.

Show moreShow less

The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease.

Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Stock analysis

Brii Biosciences Ltd (2137) currently trades at HK$1.05, while our estimate is HK$0.8800, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.6600 (bear) to HK$1.10 (bull), the price of HK$1.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Brii Biosciences Ltd reported revenue of 18.1M CNY in FY2025 versus 92.5M CNY in FY2021, a compound −33.5%/yr. Reported net income was −217M CNY in FY2025.

Key figures

Market cap HK$771M (≈ $98.3M) Micro · P/S ratio 20.3 · Return on equity −7.7% · Return on assets (EBIT) −15.3% (5-year average) · Operating margin −755% · Revenue (TTM) 34.9M CNY · Revenue growth (YoY) +24.4% · Free cash flow −288M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, 2137 screens richer than that median.

Fair Value

Bear HK$0.6600 Fair Value HK$0.8800 Bull HK$1.10
Price HK$1.05 · Downside -16.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 18
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 72
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−66.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,091.0% (2020) → −1,632.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2137 screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Brii Biosciences Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −16.2% · Above median
Profitability
Return on assets −9.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 24.4% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.28× · Cheapest 25%
P/S (12 months) 18.81× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 2137
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 2137
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 2137
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 2137
argenx SE ARGX $971.55 $908.40 −7% vs 2137
CSL Limited CSL A$201.68 A$181.40 −10% vs 2137
Moderna, Inc MRNA $250.83 $158.70 −37% vs 2137
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 2137
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 2137
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 2137

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Brii Biosciences Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Brii Biosciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2137

Frequently asked questions

Is Brii Biosciences Ltd (2137) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.8800 versus a price of HK$1.05, about 16% lower (overvalued).
What is the fair value of 2137?
Our estimate for Brii Biosciences Ltd is HK$0.8800 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$1.05.
What is the quality score of 2137?
Brii Biosciences Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Brii Biosciences Ltd (2137)?
Our calculated price target is the estimate of HK$0.8800 (as of Nov 10, 2026). Cautious scenario HK$0.6600, optimistic scenario HK$1.10. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Brii Biosciences Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.8800, about 16% lower versus a price of HK$1.05 (overvalued). Cautious scenario HK$0.6600, optimistic scenario HK$1.10. The calculation is refreshed regularly with new filings.
What is the revenue of Brii Biosciences Ltd (2137)?
Brii Biosciences Ltd reported trailing-twelve-month revenue of about 34.9M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Brii Biosciences Ltd (2137)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Brii Biosciences Ltd it is HK$0.8800 per share (as of Nov 10, 2026), against a price of HK$1.05.
Is Brii Biosciences Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2137 trades above its calculated fair value: price HK$1.05, fair value HK$0.8800, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2137?
No. The price is what the market pays today (HK$1.05); the fair value is what the company's own numbers justify (HK$0.8800). For Brii Biosciences Ltd the two are HK$0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Brii Biosciences Ltd worth?
The market values Brii Biosciences Ltd at about HK$771M (market capitalisation, as of Nov 10, 2026). Per share that is HK$1.05; our models calculate a fair value of HK$0.8800 per share.
What do the bullish and bearish scenarios say about 2137?
Our models span a range for Brii Biosciences Ltd: cautious scenario HK$0.6600, base HK$0.8800, optimistic HK$1.10 per share (as of Nov 10, 2026, price HK$1.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Brii Biosciences Ltd (2137)?
Balance-sheet figures for Brii Biosciences Ltd (as of Nov 10, 2026): return on equity −7.7%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 2137 from its 52-week high?
Brii Biosciences Ltd trades at HK$1.05, about 44% below its 52-week high of HK$1.87 and 26% above the low of HK$0.8350 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8800 is for.
Which stocks are comparable to Brii Biosciences Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Brii Biosciences Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$1.05, calculated fair value HK$0.8800 (−16%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Brii Biosciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Brii Biosciences Ltd (2137)?
The closing price on Nov 10, 2026 was HK$1.05. Our estimate is HK$0.8800, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Brii Biosciences Ltd right now?
Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Brii Biosciences Ltd

How large is the market capitalisation of Brii Biosciences Ltd (2137)?
The market capitalisation of Brii Biosciences Ltd is HK$771M (≈ $98.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Brii Biosciences Ltd (2137)?
The price-to-sales ratio of Brii Biosciences Ltd is 20.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Brii Biosciences Ltd (2137)?
The return on equity (ROE) of Brii Biosciences Ltd is −7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Brii Biosciences Ltd (2137)?
On an EBIT basis the return on assets of Brii Biosciences Ltd is −15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Brii Biosciences Ltd (2137)?
The operating margin of Brii Biosciences Ltd is −755% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Brii Biosciences Ltd (2137)?
Revenue at Brii Biosciences Ltd is growing +24.4% versus a year earlier (3y avg −29.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Brii Biosciences Ltd (2137) generate?
The free cash flow of Brii Biosciences Ltd is −288M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Brii Biosciences Ltd (2137) hold?
Brii Biosciences Ltd holds more cash than debt, 600M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Brii Biosciences Ltd in the live analysis

One click puts Brii Biosciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.